2025-12-17 - Analysis Report
Okay, here's a breakdown of the information provided for Natera Inc. (NTRA), with simple numbers first, followed by analysis:

**0. Overall Information**

*   **Ticker:** NTRA
*   **Company Overview:** Natera Inc. is a diagnostics company focused on cell-free DNA testing.

**1. Return Rate Comparison**

*   **NTRA Cumulative Return:** 132.99%
*   **VOO (S&P 500) Cumulative Return:** 100.07%
*   **Divergence (NTRA - VOO):**
    *   Current: 36.2 (percentage points)
    *   Relative Divergence: 47.4 (Meaning the divergence is near the lower half of its historical range of divergence from VOO)

**1.1. Alpha, Beta Analysis**

|            | CAGR      | MDD     | Alpha      | Beta   | Cap(B) |
|------------|-----------|---------|------------|--------|--------|
| 2015-2017  | -10.0%    | 70.1%   | -34.0%     | -0.2   | 1.2    |
| 2016-2018  | 22.0%     | 80.0%   | 6.0%       | 0.1    | 1.9    |
| 2017-2019  | 50.0%     | 80.0%   | 28.0%      | 1.0    | 4.7    |
| 2018-2020  | 186.0%    | 80.5%   | 163.0%     | 1.1    | 13.8   |
| 2019-2021  | 96.0%     | 80.5%   | 49.0%      | 1.6    | 13.0   |
| 2020-2022  | -77.0%    | 80.5%   | -76.0%     | 0.1    | 5.6    |
| 2021-2023  | -194.0%   | 76.6%   | -195.0%    | -1.1   | 8.7    |
| 2022-2024  | 8.0%      | 76.6%   | -13.0%     | -1.2   | 22.0   |
| 2023-2025  | 166.0%    | 76.6%   | 99.0%      | 0.1    | 32.4   |

*   **CAGR:** Compound Annual Growth Rate.
*   **MDD:** Maximum Drawdown (largest peak-to-trough decline).
*   **Alpha:** Risk-adjusted performance relative to the S&P 500 (positive is good).
*   **Beta:** Volatility relative to the S&P 500 (higher than 1 is more volatile).
*   **Cap(B):** Market capitalization in billions

**Analysis:**

*   NTRA has significantly outperformed the S&P 500 over some periods (e.g., 2018-2020, 2019-2021, 2023-2025). However, it has also dramatically underperformed in other periods (e.g., 2020-2022, 2021-2023).
*   The Beta values fluctuate, indicating changing volatility relative to the market. Notably, the beta is slightly negative in 2015-2017, 2021-2023 and 2022-2024.
*   The Alpha values also fluctuate wildly, reflecting the periods of significant outperformance and underperformance.
*   The MDD is consistently high, indicating significant risk and volatility.

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 227.40
*   **Previous Close:** 228.4
*   **Change:** -0.44
*   **5-day SMA:** 230.39
*   **20-day SMA:** 233.27
*   **60-day SMA:** 200.38

**Analysis:**

*   The stock price is currently slightly down from the previous close.
*   The 5-day and 20-day SMAs are above the current price, suggesting a short-term downtrend.
*   The 60-day SMA is significantly below the current price, indicating a longer-term uptrend.

**3. Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 35.25 (Approaching oversold)
*   **PPO:** -1.36 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** -2.4 (Short-term decrease)
*   **Expected Return (%):** -50.6% (Negative, indicating potential underperformance compared to the S&P 500 over the long term from the recent price point)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates the stock is nearing oversold conditions, which *could* signal a potential buying opportunity.
*   The negative PPO confirms a downtrend.
*   The hybrid signal suggests using available cash to buy 4 shares.
*   The negative expected return is a significant concern, suggesting potential underperformance long term.

**4. Recent News & Significant Events**

*   **Insider Selling:** Several reports of insiders selling shares. (Solomon Moshkevich, Director).  *This is generally seen as a negative signal.*
*   **Analyst Target Price Increase:** Barclays raised the price target to $270. *Positive.*
*   **Mixed Opinions:**  An article suggests Natera remains a "Hold" despite growth. *Neutral.*
*   **Valuation Assessment:**  An article discusses assessing Natera's valuation after a strong rally. *Indicates attention on valuation which can lead to price corrections.*
*   **Investor Confidence:** An article highlights an investor buying Natera. *Positive.*

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy
*   **Mean Rating:** 1.47 (Strong Buy)
*   **Target Price:** Average: $244.42, High: $280.00, Low: $186.00

**Analysis:**

*   Despite the insider selling news, the overall analyst sentiment remains positive with a strong buy consensus and a target price significantly above the current price.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2025-11-07 | -0.64 | 0.59 B$  |
| 2025-08-08 | -0.74 | 0.55 B$  |
| 2025-05-09 | -0.5  | 0.50 B$  |
| 2024-11-12 | -0.26 | 0.44 B$  |
| 2025-11-07 | -0.26 | 0.44 B$  |

**Analysis:**

*   Natera is not currently profitable. EPS is negative in all reported quarters.
*   Revenue shows a generally increasing trend, which is positive.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|----------------|
| 2025-09-30   | $0.59B   | 64.91%         |
| 2025-06-30   | $0.55B   | 63.41%         |
| 2025-03-31   | $0.50B   | 63.12%         |
| 2024-12-31   | $0.48B   | 62.94%         |
| 2024-09-30   | $0.44B   | 61.79%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $1.25B   | -6.99% |
| 2025-06-30   | $1.25B   | -8.10% |
| 2025-03-31   | $1.24B   | -5.40% |
| 2024-12-31   | $1.20B   | -4.50% |
| 2024-09-30   | $0.88B   | -3.60% |

**Analysis:**

*   Revenue is consistently increasing.
*   Profit Margin is high and increasing, suggesting strong pricing power or cost control.
*   Equity is increasing, showing financial health.
*   ROE is negative, confirming the company's lack of profitability.

**7. Comprehensive Analysis (Summary)**

Natera (NTRA) presents a mixed picture:

*   **High Growth Potential:** Demonstrated by historical outperformance and strong revenue growth.
*   **High Risk and Volatility:** Evidenced by high MDD, fluctuating Beta, and recent price declines.
*   **Not Yet Profitable:** Negative EPS and ROE are significant concerns.
*   **Mixed Signals:** Positive analyst ratings and target price increases are countered by insider selling and a negative expected return. The technical indicators are also mixed, with the RSI approaching oversold, but the PPO indicating a downtrend.

**Overall Recommendation:**

Due to the negative expected return (especially compared to the S\&P 500), the current downtrend indicated by SMAs and PPO, and the recent insider selling, it is recommended to do a deeper analysis of the financial aspects of the company, especially the profitability trend. Also, it is recommended to wait for confirmation of a recovery trend.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.